# Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma

> **NCT04443829** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University College, London** · enrollment: 12 (estimated)

## Conditions studied

- Primary CNS Lymphoma

## Interventions

- **BIOLOGICAL:** CD19CAR T-cells

## Key facts

- **NCT ID:** NCT04443829
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-23
- **Primary completion:** 2024-12
- **Final completion:** 2032-12
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04443829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04443829, "Immunotherapy Using CAR T-cells to Target CD19 for Relapsed/Refractory CD19+ Primary CNS Lymphoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04443829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*